Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York. ...Middle East

PR Newswire - News
Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.
Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients. HOUSTON and NEW YORK, April 1, 2024 /PRNewswire/ -- Cellenkos®, a clinical stage biotech cell therapy company focused on treating autoimmune diseases and...

Hence then, the article about cellenkos enters into sponsored research agreement with icahn school of medicine at mount sinai new york was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York. )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News